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1. Introduction 
Vaccinology as a scientific field is undergoing a dramatic development. Never before such 
sophisticated techniques and in-depth knowledge of immunological processes have been at 
hand to exploit fully the potential of protecting from as well as curing diseases through 
vaccination. In spite of great successes like eradication of smallpox in the 1970s and 
poliomyelitis elimination from all but six countries in the world (two important milestones in 
the medical history), new challenges have arisen to be faced. Rapidly changing ecosystems and 
human behaviour, an ever-increasing density of human and farmed animal populations, a 
high degree of mobility resulting in rapid spreading of pathogens in infected people and 
animals, new contacts between human and animals in endemic areas, poverty, and war 
conflicts in the third world, and many other factors contribute to the more frequent occurrence 
and rapid dissemination of new diseases. Three diseases that most heavily afflict global health 
are AIDS, tuberculosis, and malaria. As an example of new viral pathogens we can mention 
Ebola virus, SARS-coronavirus, or new strains of influenza virus (Wack & Rappuoli, 2005). 
Among re-emerging diseases of the past few years, diphteria and cholera should be 
mentioned. Moreover, multi drug-resistant bacteria frequently occur as a result of overdosing 
on antibiotics. One of the most important future challenges will be to respond promptly to 
emerging diseases such as those mentioned above. Rapid sequencing of the genome of the 
pathogen implicated the speed of the development of diagnostic tools as well as the 
identification and expression of recombinant targets for vaccines and therapeutic agents 
development (Stadler et al., 2003). Immunotherapy of cancer represents a special field, where 
anticancer vaccines could be powerful weapons/tools for long-term effective treatment.   
The progress in the vaccine development is closely related with the progress in immunology 
and molecular biology. A new term “Reverse vaccinology” was proposed by Rappuoli 
(Rappuoli, 2000) to specify a complex genome-based approach in the vaccine development. 
Unlike the conventional approach that requires a laborious process of a selection of 
individual components important for the induction of protective immune response, reverse 
vaccinology offers a possibility to use genomic information derived from in silico analysis of 
the sequenced organisms. This approach can significantly reduce the time necessary to 
identify the antigens for the development of a candidate vaccine and enables a systematic 
identification of all potential antigens of pathogens including those which are difficult or 
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currently impossible to culture. Of course, this approach is limited to the identification of 
protein or glycoprotein antigens, omitting such important vaccine components as 
polysaccharides and glycolipids. Nevertheless, reverse vaccinology can enable scientists to 
systemically classify the potential protective antigens, thereby helping to improve the 
existing vaccines and to develop efficient preparations against virtually any pathogen that 
has had its genome sequence determined. 
As regards the process of activation of the immune system to produce an adaptive immune 
response, it is generally observed that the antigen by itself may not be adequate as a 
stimulating agent. Many potential antigens have no apparent immunizing activity at all 
when tested alone. In general, seamy side of pure recombinant protein antigens and 
synthetic peptide antigens is their poor immunogenicity. Therefore, potent adjuvants are 
required for highly purified antigen-based vaccines to be effective. 
2. Adjuvants 
2.1 Toll-like receptors and pathogen-associated molecular patterns 
The word adjuvant is derived from the Latin root of adjuvare, which means to help. Thus, an 
adjuvant can be defined as any product which increases or modulates the specific humoral 
or cellular immune response against an antigen. The interaction between the innate and the 
adaptive immune responses is paramount in generating an antigen-specific immune 
response. The initiation of innate immune responses begins with the interaction of 
pathogen-associated molecular patterns (PAMPs) on the pathogen side with pattern-
recognizing receptors (PRR) such as Toll-like receptors (TLRs) on the host cells involved in 
the innate immunity (e.g., dendritic cells). A major functional criterion commonly used for 
the evaluation of various new adjuvants involves their ability to stimulate the innate 
immunity cells. This would include engaging and other PRRs and the co-receptors and 
intracellular adaptor signalling proteins with which they are associated. PAMPs and their 
derivatives are utilized by adjuvant developers to harness the power of innate immunity to 
channel the immune response in a desired direction.  
Based on the identification of several TLRs and PAMPs recognized by them, various PAMP 
agonists were tested as adjuvans. Examples of TLR-PAMP specific interaction include 
bacterial or viral unmethylated immunostimulating CpG oligonucleotides interacting with 
TLR9, liposaccharide and its component monophosphoryl lipid A (MPLA) interacting with 
TRL4. These two types of adjuvants are in advanced stage of testing in clinical trials and 
some already licensed vaccines contain MPLA in liposomal form. Further liposomal or lipid-
based particle formulations of both CpG and MPLA are under development and testing. 
2.2 Muramyl dipeptide and other muropeptides 
Very specific group of PAMPs is represented by peptidoglycans (PGN). Both Gram-positive 
and Gram-negative bacteria contain PGN which consists of numerous glycan chains that are 
cross-linked by oligopeptides. These glycan chains are composed of alternating N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) with the amino acids 
coupled to the muramic acid. Muropeptides are breakdown products of PGN that bear at 
least the MurNAc moity and one amino acid (Traub et al., 2006). One of the prominent 
muropeptides is muramyl dipeptide (MDP), which is known since the 1970s.  
Recently, the molecular bases for MDP recognition and subsequent stimulation of the host 
immune system have been uncovered. Myeloid immune cells (monocytes, granulocytes, 
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neutrophils, and also DCs) possess two types of intracellular receptor for MDP, namely NOD2 
and Cryopyrin (inflammasome-NALP-3 complex) (Agostini et al., 2004; Girardin and Philpott, 
2004; McDonald et al., 2005). These two receptors recognize MDP/MDP analogues minimal 
recognition motifs for bacterial cell wall peptidoglycans (Girardin & Philpott, 2004; McDonald 
et al., 2005). NOD2 is also expressed in specialised epithelial cells, Paneth cells, localised in 
crypts of Lieberkün, which are producers of antimicrobial peptides having direct antimicrobial 
activity together with signalling functions within the immune system. Induction of an innate 
immune response against Cryptosporidium parvum infection by the liposomal preparation of 
lipophilic norAbuGMDP was demonstrated by us in newborn goats (Turanek et al., 2005) and 
this data is supportive of the present view of the role of MDP recognition in inducing both 
specific and innate immune responses.  
Here GMDP abbreviates N-acetylglucosaminylmuramyl dipeptide. Another recently 
reported sensor of MDP is Cryopyrin (also known as CIAS1 and NALP3), which is a 
member of the NOD-LRR family (Agostini et al., 2004). Cryopyrin is a part of the 
inflammasome complex that is responsible for processing caspase-1 to its active form. 
Caspase-1 cleaves the precursors of interleukin IL-1β and IL-18, thereby activating these 
proinflammatory cytokines and promoting their secretion. IL-1β is known to be a strong 
endogenous pyrogen induced by MDP. We showed that norAbu-MDP analogues were not 
pyrogenic even at a high concentration, much higher than the concentrations used for 
vaccination. We supposed that the modification introduced into the structure of MDP to get 
norAbuMDP analogues had not changed their affinity to NOD2 but had substantially 
decreased the affinity to cryopyrin. This hypothesis is in accordance with our data on 
pyrogenicity and is being currently tested in appropriate in vitro models. In addition, 
murabutide, another nonpyrogenic derivative of MDP was shown not to be able to induce 
detectable level of IL-1ß in sera of treated volunteers (Darcissac et al., 2001). 
The expression of NOD2 in dendritic cells is of importance with respect to the application of 
MDP analogues as adjuvants. Nanoparticles like liposomes are able to provide a direct co-
delivery of a danger signal (e.g., MDP) together with the recombinant antigen and therefore 
to induce an immune response instead of an immune tolerance. This is especially important 
for weak recombinant antigens or peptide antigens. Clearly, the recognition of MDP by DCs 
is crucial for the application of MDP analogues as adjuvants. Although the immuno-
stimulatory effects of MDPs have been described for over three decades, the process of 
molecular recognition and binding of MDP/MDP analogues to NOD2 and cryopyrin 
receptors remains unclear. Within the cell, MDP/MDP analogues trigger intracellular 
signalling cascades that culminate in the transcriptional activation of inflammatory 
mediators such as the nuclear transcription factor NF-κB. The biological effects of muramyl 
peptides have been described for over three decades. The mechanism underlying their 
internalization of MDP to the cytosol, where it is sensed by NOD2 and cryopyrin, remains 
unclear. Liposomes probably play the role of efficient carriers for MDP and its analogues on 
the pathway from extracellular milieu into the cytosol, where they trigger intracellular 
signalling cascades that culminate in transcriptional activation of inflammatory mediators 
such as the nuclear transcription factor NF-κB pathway. In case of liposomal formulation of 
various MDP analogues, the relevant intracellular pharmacokinetics, molecular recognition 
and binding affinity towards NOD2 and Cryopyrin remain to be determined. Such 
differences found for various MDP analogues are responsible for their various biological 
activities (e.g., pyrogenicity, ability to induce the innate immune response etc.) and, 
therefore, could be utilised for a precise tuning of the intensity and type of immune 
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response. Since the discovery and first synthesis of MDP, about one thousand various 
derivatives of MDP have been designed, synthesised, and tested to develop an appropriate 
drug for an immunotherapeutic application that would be free of the side effect exerted by 
MDP. The main side effects of MDP are pyrogenicity, rigor, headache, flue-like symptoms, 
hypertension etc. Only several preparations reached the stage of clinical testing and only 
Mifamurtide (Fig. 1) was approved for the treatment of osteosarcoma.  
2.2.1 Mifamurtide (MTP-PE)  
In pyrogenicity test in rabbits, pyrogenic activity of Mifamurtide i.v. was comparable to that 
of MDP. In several studies with cancer patients refractory to standard therapy, infused with 
liposomal Mifamurtide at a dose range of 0.01 – 1.8 mg/m2/dose, dose-dependent fever (in 
common about 70% of patients) and rigor (about 50% of patients) were the most prominent 
from a number of acute systemic toxicities (Creaven et al., 1990). 
Mifamurtide was also assayed as an additional immunomodulator in an MF59-adjuvanted 
influenza virus vaccine (Keitel et al., 1993) and HIV-1 vaccine (Keefer et al., 1996); systemic 
symptoms including fever, chill, and nausea made these vaccines unsuitable for clinical use. 
Today, the main interest lies in clinical trials for liposomal Mifamurtide as a component of 
three-drug chemotherapy of osteosarcoma (Anderson P.M, 2006; Anderson et al., 2010).  
2.2.2 Romurtide (Muroctasine)  
In healthy volunteers, s.c. administration of Romurtide (Fig. 1) at a dose of 200 µg induced - 
besides local pain and redness - an approximately 1º C increase in body temperature with 
great individual variability in the course of pyrogenicity curves; normalization occurred 
within 48 hours (Ichihara et al., 1988). Fever accompanied by chill and headache was also 
the most common adverse reaction in cancer patients treated with Romurtide at a dose 
range of 100 – 400 µg/dose s.c. for the restoraion of haemopoiesis after chemotherapy 
and/or radiotherapy (Tsubura et al., 1988) (Azuma & Seya, 2001; Tsubura et al., 1988). 
2.3 nor-Muramyl glycopeptides 
We found that a combination of structural modifications both in the saccharide and peptide 
moiety of MDP and GMDP molecules leads to significant suppression or elimination of 
pyrogenicity and potentiation of immune-stimulatory activity (Fig. 2). The substitution of 
muramic acid with normuramic acid and L-alanine with L-2-aminobutyric acid has lead, in the 
case of the norAbu-MDP molecule, to a decrease of pyrogenicity and, at the same time, to the 
potentiation of immunoadjuvant activity. If the same structural change is carried out in GMDP 
molecule, a non-pyrogenic and highly immunoadjuvant analog, norAbu-GMDP is obtained. 
Furthermore, it has been demonstrated that by the introduction of bulky lipophilic residues 
into the molecules of these analogs, immunomodulatory activity can be effectively profiled, 
while the favourable pharmacological parameters of the parent structures are retained. These 
facts motivated our aims to design and prepare the new groups of lipophilic analogs of 
norAbu-MDP and norAbu-GMDP, which differ in the character and topology of the lipophilic 
residue. We primarily aimed to modify their immunopharmacologic parameters. norAbu-
MDP-Lys(L18), i.e. MT05, belongs to them. In accordance with our premise, all the new 
compounds were nonpyrogenic (rabbit test), and the character and topology of the lipophilic 
residue had a significant effect on their immunologic parameters. As an example, the 
structural differences between norAbu-MDP-Lys(18) (MT05) and Romurtide, which 
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influenced the profile of the effects and lead to the elimination of pyrogenicity, are depicted in 
Fig. 3. (Ledvina M., Turánek J., Miller A.D., Hipler K.: Compound (Adjuvants): PCT appl., WO 
2009/11582 A2, 2009.) 
 
 
Fig. 1. MDP derivatives developed by various pharmaceutical companies as adjuvants and 
immunotherapeutics.  
 
 
Fig. 2. Transformation of MDP into norAbu-MDP and GMDP into norAbuGMDP and 
formulae of their hydrophobised derivatives suitable for development of lipid-based 
adjuvants.  
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Fig. 3. Structural differences between Romurtide and MT05. 
3. Liposomes 
3.1 General characterisation of liposomes 
Liposomes, membrane-like spherical structures consisting of one or more concentric lipid 
bilayers enclosing aqueous compartments were first formulated and described by Alex 
Bangham in 1965 (Bangham et al., 1965), and have become a useful tool and model in 
various areas of science. Liposomes represent the oldest and the most explored nano- and 
micro systems for biological studies on model membranes and for medical applications, 
especially for drug formulations, because they eliminate or suppress organ-specific toxic 
side-effects of various drugs (Allen, 1997). Through their 46-year history, liposomes have 
been approved as suitable delivery systems for applications ranging from cosmetics and 
dermatology, anti-infection and anticancer therapy and diagnostics up to human as well as 
veterinary vaccines (Gregoriadis, 1995).  
Liposomes are classified in terms of number of bilayers enclosing the sequestered aqueous 
volume as follows: unilamellar, oligolamellar, and multilamellar. Unilamellar vesicles can 
be further divided into small unilamellar vesicles (SUVs) with a large curvature, and large 
unilamellar vesicles (LUVs) with a low curvature and hence, with properties similar to those 
of a flat surface. Multilamellar vesicles (MLVs) are liposomes that represent a heterogenous 
group in terms of size and morphology (Cullis et al., 1987). Lipid composition, size and 
morphology are variables determining the fate of liposomes in biological milieu; therefore, 
the selection of suitable method for the preparation of liposomal drugs and vaccines is of 
importance in respect to subsequent animal experiments and future successful marketing of 
the product. Schematic structures of various types of liposomes as well as realistic picture 
obtained by cryoelectron microscopy are presented in Fig. 4.  
3.2 Liposome-based vaccines 
The use of liposomes as vaccine adjuvants was first described by Allison and Gregoriadis in 
1974 (Allison & Gregoriadis, 1974). Since that time, numerous studies were performed and 
proved that liposomes can be used to enhance the immune response towards a large variety of 
peptide and protein antigens derived from various microbial pathogens as well as tumours.  
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A) Photograph of various liposomal structures by cryoelectron microscopy. B) Schema of types of 
liposomes: SUV – small unilamellar vesicle, LUV - large unilamellar vesicle,, MLV – multilamellar 
vesicle, MVV – multivesicular vesicle 
Fig. 4. Schematic representation of various morphological classes of liposomes and their real 
image obtained by cryoelectron microscopy. 
The potential for the participation of liposome-based recombinant vaccines on the human 
and veterinary vaccine market is very promising (Adu-Bobie et al., 2003). Liposomal 
vaccines have been around for about 30 years and plenty of liposome variants have been 
developed; some of them with evident immune-stimulating properties and an attractive 
safety profile which resulted in registered products on the market or preparations in 
advanced stages of clinical testing. Liposomal hepatitis A vaccine is the first formulation of 
liposomes to become licensed for clinical use in humans (Gluck et al., 1992) (Hepatitis A - 
HepA, Epaxal http://www.crucell.com/Products-Epaxal). Epaxal liposomes contain 
influenza hemagglutinin protein which facilitates their binding and endocytosis by specific 
receptor on antigen presenting cells. Such forms of liposomes are called virosomes. 
Liposomes represent almost ideal carrier system for the preparation of synthetic vaccines 
due to their biodegradability and versatility as regards the incorporation of quite a number 
of various molecules having different physico-chemical properties (the size of the molecule, 
hydrophilicity or hydrophobicity, the electric charge).  
The molecules and antigens can be either sterically entrapped into the liposomes (the 
internal aqueous space), or embedded into the lipid membrane (e.g., membrane-associated 
proteins/antigens) by hydrophobic interactions. Further, they can be attached to either the 
external or the internal membrane by electrostatic, covalent or metallo-chelating 
interactions. It is possible to encapsulate simultaneously various compounds into the 
liposomes: hydrophilised/lipophilised adjuvants (e.g., MPL A, CpG oligonucleotides, MDP 
and its analogues), soluble or membrane protein antigens, and ligands for the targeting to 
specific receptors on the antigen-presenting cells. Further, liposomes can be coated with 
mucoadhesive biopolymers, or undergo surface-charge modifications (e.g., by cationic 
lipids) (Altin & Parish, 2006).  
As a great advantage, liposomes can be used for the preparation of self-assembling hybrid 
supramolecular nanosystems such as proteoliposomes, which can combine liposomal 
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nanoparticles with suitable immunopotentiating/adjuvant molecules (e.g., MPL A, CpG 
oligonucleotides, MDP, and its analogues). 
3.3 Liposomes as antigen carriers 
Structural diversity of liposomes permits tailoring of liposome-based vaccines to obtain an 
optimal adjuvant effect for a particular antigen. Their safety profiles and ability to induce an 
immune response makes them likely to be included in vaccine formulations. Liposomal 
formulations offer several major advantages. They can (1) prevent degradation of the 
delivered antigens and adjuvants; (2) allow membrane proteins to reconstitute and preserve 
their antigen structure; (3) increase the antigenic effect of weak immunogens; (4) target 
antigen-presenting cells (APCs) and direct the antigen to MHCI or MHCII presentation; (5) 
contain the antigen and adjuvant molecules in one particle, thus functioning simultaneously 
as a delivery system and a vaccine adjuvant; and (6) reduce the antigen and adjuvant doses 
required for an immune response and controlled release. Therefore, liposomes provide a 
safe and effective platform for construction of subunit vaccines. 
With respect to the physico-chemical nature of liposomes and phospholipid bilayers, the 
liposomes represent one of the most versatile structures for the preparation of drug delivery 
systems. Both hydrophobic and hydrophilic protein or peptide antigens can be associated 
with liposomes. Generally, antigens can be associated with liposomes in two ways and it is 
known that the encapsulated liposomal antigens induce a different immune response than 
the surface-linked antigens in both humoral (Shahum & Therien, 1988) and cell-mediated 
immunity (Fortin et al., 1996). If entrapped into the internal aqueous space of a liposome, the 
protein or peptide antigen is protected against proteolytic degradation and the antigen 
clearance is decreased. On the other hand, the liposomal membrane represents a barrier 
restricting the interaction of the antigen with and its recognition by B-cells. Especially, the 
stable multilamellar liposomes were found to be low immunogenic (Shek & Heath, 1983) 
and the antibody response reached is low or absent when the liposomes are made of lipids 
with a high transition temperature; in other words, when they are composed of saturated 
phospholipids (Gregoriadis et al., 1987). These liposomes are very stable in body fluids as 
well as in digestive tract and prevent a release of the entrapped antigen. Also the interaction 
of the encapsulated antigens with B-cells is limited. The fluidity of liposomes was found to 
be an important parameter also for the immune response towards a surface-linked antigen. 
Again, more fluidic liposomes composed of unsaturated phospholipids are more efficiently 
phagocytosed by APC and induce a one order of magnitude higher immune response than 
rigid liposomes composed of saturated phospholipids (Uchida & Taneichi, 2008).  
Liposomes are potentially very useful for the construction of vaccination systems given their 
facile biodegradability and versatility as carriers for varieties of molecules having different 
physico-chemical properties (such as size, hydrophilicity, hydrophobicity, or net electrical 
charge). Liposomes also offer the possibility to associate or entrap simultaneously more than 
one type of molecules. Of particular interest to us has been the co-association of hydrophilic 
or lipophilic adjuvants (e.g., monophosphoryl lipid A [MPL A], CpG oligonucleotides, 
muramyl dipeptide (MDP), and/or MDP lipophilic analogues) with soluble or membrane 
protein antigens or ligands for the targeting of specific receptors on antigen-presenting cells. 
The molecules and antigens can be either sterically entrapped into the liposomes (the 
internal aqueous space), or embedded into the lipid membrane (e.g., membrane-associated 
proteins/antigens) by hydrophobic interactions (Fig. 5). The ligands for the targeting to 
specific receptors on the antigen-presenting cells can significantly enhance the intensity of 
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the immune response (Altin & Parish, 2006). For the mucosal application, the liposomes can 
be coated with mucoadhesive biopolymers or modified with surface-charge modifiers (e.g., 
cationic lipids). In this way, liposomes become a versatile platform that represents a real 
multifunctional vaccination carrier.  
The importance of liposomes for the effective co-administration of adjuvants could be 
demonstrated using MDP as an example. MDP has a weak immunoadjuvant activity in 
aqueous solution due to its rapid excretion into urine. Appropriate formulations of 
hydrophilic MDP in “water in oil” emulsions (Parant et al., 1979) or liposomes were used to 
harness its full adjuvant potenital (Tsujimoto et al., 1986). Some lipophilic derivatives of 
MDP like B30-MDP and MDP-Lys (L18) were synthesised and tested as adjuvants for 
recombinant hepatitis B surface antigen (Tamura et al., 1995) or influenza surface antigens 
hemagglutinin and neuraminidase (Nerome et al., 1990). We used new synthetic 
nonpyrogenic lipophilic analogues of norAbu-MDP modified at a peptide part by 
hydrophobic ligands (Fig. 2) and these well defined synthetic molecules were used for the 
first time in combination with metallochelating liposomes to construct an experimental 
recombinant vaccine. Surprisingly, we have found that at certain surface density of 
lipophilic analogues of norAbu-MDP (about 5 mol % of total liposomal lipid), the liposomes 
are promptly recognised and phagocytosed by human dendritic cells. The phagocytosis is 
about one order of magnitude higher than that of proteoliposomes or liposomes lacking 
norAbu-MDP adjuvant. This finding implicates an existence of receptors on dendritic cells, 
which can recognise some molecular pattern formed by the hydrophilic part of norAbu-
MDP exposed on the liposomal surface (illustration of this phenomenon is in Fig. 12B).  
 
 
a) physical entrapment inside the liposome (blue protein); b) reconstitution of membrane protein in 
lipid bilayer via hydrophobic transmembrane domain (yellow protein); c) anchoring of lipidised protein 
onto liposomal surface or attachment of recombinant protein onto the liposomal surface by covalent 
bond using activated lipids (red protein); d) attachment of recombinant protein onto the liposomal 
surface by non-covalent bond using metallochelating lipids 
Fig. 5. Association of protein antigen with liposome. 
3.4 Methods of liposome preparation  
The laboratory and industrial procedures for the liposome preparation have been 
established and liposomes have been approved by FDA for biomedical applications. A 
variety of procedures for the preparation of various types of liposomes has been developed 
and reported in several reviews and monographs (Gregoriadis, 1992; Woodle & 
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Papahadjopoulos, 1988). To classify these methods, they were arranged in three categories: 
1) mechanical dispersion methods such as hand shaking or vortexing, sonication, and high 
pressure homogenisation; 2) detergent-solubilizing dispersion methods including 
solubilized lecithin dispersion with sodium cholate or octylglucoside; and 3) solvent 
dispersion methods such as ethanol injection, ether infusion, and reverse-phase evaporation. 
These primary processes can be linked with secondary processes such as high-pressure 
homogenisation or extrusion through polycarbonate filters of various pore size, which are 
easy ways to prepare liposomes of a desired size and morphology (Barnadas-Rodriguez & 
Sabes, 2001; Berger et al., 2001; Cullis, 1987; Hope et al., 1985; Perrett et al., 1991; Turanek, 
1994; Woodle & Papahadjopoulos, 1988; Schneider et al., 1995).  
The stability of proteins is limited and not all the methods are useful for the preparation of 
proteoliposomes, especially if the protein is to be entrapped inside the liposome. The 
detergent dilution method is characterized by very mild conditions during the process and 
is suitable for the reconstitution of membrane proteins. Because many recombinant proteins 
tend to precipitate, this method is also useful to work with these protein antigens. Next 
paragraph describes in detail a modified detergent dilution method for the preparation of 
proteoliposomes. 
3.5 Preparation and characterization of metallochelating liposomes 
Because the preparation of metallochelating liposomes represents a post-forming 
modification of liposomes, it avoids a denaturation of proteins owing to the process used for 
the liposome production. Therefore, nearly all the methods mentioned above could be used 
to prepare more or less monodisperse liposomes. Here we describe in brief a modification of 
the detergent removal method, which is suitable for the preparation of very monodisperse 
unilamellar liposomes that are useful for structural studies by various techniques (e.g., TEM, 
dynamic light scattering, and gel permeation chromatography). 
When essentially unilamellar monodisperse liposomes of spherical shape are needed (which is 
a prerequisite for a precise monitoring of the proteoliposome formation by dynamic light 
scattering), the detergent removal method is preferred to the other methods. The method is 
based on the transformation of phospholipid micelles stabilized by detergent with high critical 
micellar concentration (CMC) (e.g., cholate) to desk micelles and finally to vesicles during the 
process of detergent removal (Zumbuehl & Weder, 1981) (Fig. 6). The mild conditions 
provided by this method are advantageous for the preparation of proteoliposomes, especially 
for the reconstruction of membrane proteins (Rigaud & Levy, 2003) like viral or bacterial 
antigens or recombinant his-tagged proteins that are often prone to precipitation.  
There are many variants of the detergent removal method, e.g., the dilution of the solution 
of mixed micelles, gel permeation chromatography, a simple dialysis or the controlled one 
in a special apparatus, cross-flow filtration, adsorption on beads, etc. (Schubert, 2003). The 
application of the flow-through ultrafiltration cell represents a new approach to the 
detergent removal method (Masek et al., 2011a). The linkage of the cell with systems like 
FPLC facilitates automation of the whole procedure and manipulation with the sample. The 
full control over the dialysis rate and the removal of the undesired residua (e.g., detergent, 
organic solvents, protein solubilizers) is ensured and various steps like an addition of 
required components through an injection valve during various stages of the liposome 
formation are easy to perform without breaching the sterile conditions. In this case, the 
sterile filter inserted in front of the cell inlet ensures that the sterility is kept during the 
whole process (Fig. 7). The low dead volume of the cell is of great importance for the 
preparation of liposomes and proteoliposomes in small laboratory scale. However, this 
arrangement enables also very easy up-scaling of the whole technology. A precise control 
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over the rate of the detergent removal yields a final liposomal preparation of high 
monodispersity (PDI within the range of 0.05 - 0.06), which is shown to be reached routinely 
(Fig. 8). This monodispersity is better than those obtained by the dialysis method performed 
in the dialysis bags or slides (produced by Pierce) (PDI ≈ 0.08-0.12). 
The size of the mixed micelles (≈5-6 nm; see Fig. 8) used by us for the preparation of 
liposomes is in good correlation with the Small's mixed micellar model proposing the 
structure of a small phospholipid bilayer disc stabilised at its hydrophobic edges by the 
molecules of cholate (Small, 1971; Schubert, 2003). 
The process of the formation of the monodisperse liposomes is in good accordance with the 
proposed kinetic model of the micelle-vesicle transition based on a rapid formation of disk-
like intermediate micelles followed by a growth of these micelles up to their critical size and 
their subsequent closure to form vesicles. The final size of the liposomal preparation could 
be controlled by ionic strength of the buffer used for the preparation of the micelles ( Fig. 9). 
An increase of the NaCl concentration reduces CMC of cholate and shields the negative 
charge of the mixed micelles. These two factors are responsible for the formation and 
stabilisation of the large discoid bilayer micelles that are transformed into the larger 
liposomes (Schubert, 2003). 
Various additives like bilayer stabilising sugars (e.g., sucrose) or recombinant protein 
solubilizers (e.g., urea, guanidine) are compatible with this method and can shift the size of 
the liposomes into the required range (Walter et al., 2000). Some recombinant proteins (e.g., 
circovirus envelope protein), which tend to precipitate in the absence of stabilizing buffers 
(imidazole and urea stabilizing buffer) were successfully linked onto metallochelating 
liposomes by one-step procedure based on the addition of the protein into the mixed micelle 
solution prepared in protein stabilizing buffer and transforming into proteoliposomes 
during the ultrafiltration procedure (Turánek, unpublished results).  
 
 
Adapted: R. Schubert, Methods Enzymol. 367 (2003) 46–70. 
Fig. 6. Principle of detergent removal method and formation of liposomes from mixed bile 
salt-phospholipid micelles. 
Small mixed micelles are fused in disc phospholipid micelles stabilized at edges by 
detergent. Further removal of detergent induces formation of large disc micelles which 
spontaneously vesiculate after reaching a critical size. 
The transformation of micelles into liposomes during the ultrafiltration removal of cholate is 
a critical step affecting the final quality of liposomes. This process is easy to be monitored by 
DLS. The removal of cholate induced a formation of disc micelles, which was reflected by an 
increase of the micelle size and eventually by a formation of liposomes (Fig. 10). The process 
of liposome formation had been completed before the CMC of cholate was reached, as 
shown by the dashed vertical line. This line divides the flow-through volume axis into the 
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left part, where micelles do predominantly exist and are transformed into liposomes, and 
the right part, where liposomes represent the main lipid form, while the residual detergent 
and other low molecular weight contaminants (e.g., traces of ethanol or tetrahydrofuran 
used to solubilize the lipids) are continuously removed by the process of ultrafiltration. 
 
 
(A) Schematic illustration of the ultrafiltration cell. (B) Photograph of the ultrafiltration cell in detail 
(pink: LR-PE-labelled liposomes inside the cell). (C) Schematic illustration of the linkage of the 
ultrafiltration cell with the FPLC system. (D) Photograph of the system 
Fig. 7. System for preparation of liposomes by removal of detergent using ultrafiltration.  
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A) Size distribution of micelles and liposomes. The hydrodynamic diameters of the micelles and 
liposomes were determined by dynamic light scattering instrument NanoSizer NS (Malvern, UK) at  
25 °C. Silica cuvette of 45-µl volume (Hellma, Germany) was used. (B) TEM micrograph of 
monodisperse liposomal preparation. (C) AFM micrograph of monodisperse liposomal preparation 
Fig. 8. Size distribution of micelles and metallochelating liposomes analysed by dynamic 
light scattering and visualization of liposomes by TEM and AFM. 
 
 
 
Fig. 9. Effect of ionic strength on the size distribution of liposomes prepared by detergent 
removal method.  
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Fig. 10. Transformation of micelles into liposomes during ultrafiltration monitored by DLS. 
The dashed vertical line indicates the ultrafiltrate volume, when the CMC of sodium cholate 
was reached. This line divides the flow-through volume axis into the leftpart, where 
micelles do predominantly exist and are transformed into liposomes, and the right part, 
where liposomes represent the main lipid form, while residual detergent and ethanol/THF 
are continuously removed by the process of ultrafiltration. 
4. Metallochelating bond and its application for construction of 
proteoliposomes 
With respect to a potential application for the construction of vaccines, the question of in 
vitro and especially in vivo stability is of great importance. This problem could be divided 
into two fields. First, the stability of the liposomes themselves and second, the effect of the 
components presented in biological fluids (e.g., proteins and ions) on the stability of the 
metallochelating bond. It is beyond the scope of this chapter to address thoroughly this 
particular question. However, the GPC data indicate a good in vitro stability of the 
proteoliposomes containing recombinant His-tagged Outer surface protein C from Borrelia 
burgdorferi (rOspC) designated rOspC–HisTag during the chromatographic process, within 
which they experience a shear stress and dilution.  
Also, the data on the incubation of rOspC-HisTag proteoliposomes in serum at 37 °C 
demonstrated the stability of the metallochelating bond linking the protein to the 
liposomal surface. In fact, in vivo fate of liposomes after the intradermal administration is 
different than that following an intravenous injection. First, dilution of proteoliposomes is 
not so rapid and second, the ratio of tissue fluid proteins to proteoliposomes is more 
favourable to proteoliposomes owing to their relatively high concentration at the site of 
application. Moreover, the flow rate of the tissue fluid within intradermal extracellular 
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matrix is considerably lower than that of the muscle tissue or blood vessels. This fact is 
often overlooked. The stability of metallochelating bond probably depends also on the 
character of a particular protein. The study by Ruger shows that the single-chain Fv Ni-
NTA-DOGS liposomes are unstable in human plasma and the majority of single-chain Fv 
fragments (anti CD 105) are released from the liposomal surface, which results in a lost of 
the specific targeting performance to the cells expressing a surface protein endoglin (CD 
105) (Ruger et al., 2006). On the other hand, Ni-NTA3 –DTDA liposomes with single-chain 
Fv fragments (anti CD11c) bound onto the liposomal surface were able to target dendritic 
cells in vitro as well as in vivo. The application of the three-functional chelating lipid Ni-
NTA3 –DTDA probably endows the metallochelating bond with a higher in vivo stability 
(van Broekhoven et al., 2004). Application of Ni-NTA-DOGS liposomes for the 
construction of experimental vaccine against sytemic Candida infection based on Candida 
Heat shock protein 90 kDa (rHSP90-HisTag) showed good stability in serum as well as 
strong immune response against recobinant rHSP90-HisTag antigen in mice (Masek et al., 
2011b). 
In vivo activity (immunogenicity) was also demonstrated for antigens associated with 
ISCOM particles via metallochelating lipid dipalmitoyliminodiacetic acid (Malliaros et al., 
2004) and a peptide antigen associated with liposomes via Ni-NTA-DOGS (Chikh et al., 
2002). Generally, metal ions, physico-chemical character of the metallochelating lipids and 
their surface density on the particles belong to the factors that could be optimized to get a 
required in vivo stability and, therefore, a strong immune response. The design and 
synthesis of new metallochelating lipids might accelerate a development and application of 
metallochelating liposomes for the construction of drug delivery systems and vaccines. 
Besides Ni2+, other divalent ions such as Zn2+, Co2+, Fe2+, and Cu2+, have to be considered 
and experimentally tested as well. 
 
 
Fig. 11. Schematic illustration of recombinant His-Tagged protein bound onto the surface of 
metallochelating liposome (A) and formulae of metallochelating lipids NTA-DOGS (B), 
NTA–DTDA (C), trivalent NTA3 –DTDA (D). 
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5. Metallochelation liposomes for construction of experimental recombinant 
vaccines 
Only few papers report the implementation of the metallochelating lipids in the attachment 
of the recombinant proteins or synthetic peptides with His-Tag anchor (short peptide 
consisting of 4 to 6 molecules of histidine). Both reversible character and high affinity of the 
metallochelating bonds are very useful for the preparation of various self-assembling supra-
molecular structures useful for the construction of experimental vaccines (Chikh et al., 2002; 
Malliaros et al., 2004; Masek et al., 2011a; Masek et al., 2011b). As an example of synthetic 
liposome-based recombinant vaccine we can use metallochelating liposomes and 
recombinant antigen rOspc-6HisTag derived from the pathogen Borrelia burgdorferi. 
5.1 rOspC antigen Borrelia as an example for construction of metallochelation 
liposome-based vaccines 
Lyme disease or Lyme borreliosis is an infectious disease caused by spirochetes of the Borrelia 
burgdorferi sensu lato complex vectored by ticks of the genus Ixodes. At least three species are 
pathogenic for humans, B. burgdorferi sensu stricto, B. afzelii, and B. garinii. The initial stage of 
Lyme disease is commonly associated with skin rash occurring within few weeks after the tick 
bites. Later the infection can spread to bloodstream and insult of joints, heart, and nervous 
system. Although not common, some patients experience late stage symptoms like arthritis, 
nervous system complications, or acrodermatitis chronica atrophicans. Here, slower response 
to antibiotics therapy, sometimes taking weeks or months to recover, or eventually, incomplete 
resolution is observed. In a few cases, antibiotic-refractory complications persist for months to 
years after antibiotic therapy, most likely due to infection-induced autoimmunity. Therefore, 
alternative approaches such as preventive immunisation are needed, mainly in the endemic 
areas (Krupka M, 2007; Tilly et al., 2008).  
Protective immune response to Borrelia involves non-specific activity of complement, 
phagocytic cells and Borrelia-specific Th1-dependent response leading to production of 
complement-activating antibodies, in mouse presented mostly by IgG2a (IgG2b). During 
natural infection, nevertheless, Borrelia and tick saliva modulate the immune response toward 
non-protective Th2 type response, associated with production of neutralizing, poorly 
opsonizing Borrelia-specific antibodies (Vesely et al., 2009). Borrelia outer surface proteins 
OspA and OspC are among the most promising antigens for elicitation of opsonizing 
antibodies. The applicability of OspA antigen is limited because Borrelia expresses it mainly in 
the tick and the antibodies thus should act outside of the vaccinee’s organism (Pal et al., 2000). 
Therefore continuously high level of OspA-specific antibodies is required to prevent Borrelia 
transfer. In contrast, OspC is expressed during the transfer and the initial stage of infection. In 
this case the vaccine-induced immune memory has enough time to initiate the production of 
opsonizing antibodies preventing Borrelia spreading (Tilly et al., 2006).  
OspC antigen can be used here as an example of reverse vaccinology approach. Full length 
recombinant OspC is difficult to prepare in high yield and purity. Production of Osp-s for 
vaccination purposes is hindered by low yield of fully processed lipidized Osp antigens or 
low immunogenicity of their non-lipidized versions. In our experiments, removing of N’ 
terminal lipidation signal was associated with an increase of the recombinant protein yield 
and purity but, as demonstrated also for other Borrelia lipoproteins, a decrease in 
immunogenicity (Erdile & Guy, 1997; Gilmore et al., 2003; Lovrich et al., 2005; Weis et al., 
1994). Induction of OspC-specific opsonizing antibodies to non – lipidised OspC could be 
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enhanced by appropriate adjuvants and carriers like such as various modification of 
liposomes. It was reported that immunisation of mice with non-lipidated OspC in strong 
adjuvants (Complete Freund’s Adjuvant, TiterMax, or Alum) could induce intense OspC-
specific antibody responses (Earnhart et al., 2007; Earnhart and Marconi, 2007; Gilmore et 
al., 1996; Gilmore and Mbow, 1999; Ikushima et al., 2000). Here we demonstrated that 
similarly strong response could be elicited by immunisation of experimental mice with 
metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbu-MDP as a 
potent adjuvant molecule. 
 
 
A) Scheme of metallochelating liposome with His-Tag recombinant protein antigen bound to the 
surface. Lipophilic nor-AbuMDP analogue as adjuvant is exposed on the surface of proteoliposome; B) 
Upper photograph (confocal microscop) shows human dendritic cell with phagocytosed prototypical 
vaccination nanoparticles cumulated in giant lysozomes (green – HLA-DR marked with antiHLA-DR 
antibodies; red – Lyssamine-rhodamine labelled vaccination particles). Lower photograph (Hofman 
modulation contrast and fluorescence microscopy) shows dendritic cells with accumulated vaccination 
particles inside (red fluorescence) 
Fig. 12. Schematic drawing of prototypical recombinant protein vaccination nanoparticle 
and interaction with human dendritic cells. 
5.2 Structure of OspC metallochelating proteoliposome    
Protein-His-Tag/metallochelating lipid complex is anchored in phospholipid bilayer by its 
lipid moiety. Egg yolk or soya phosphatidyl choline contain large portion of unsaturated 
fatty acids, therefore DOGS-NTA lipid is freely miscible with these lipids and phase 
separation do not occur in liposomal bilayer. In other words, contribution of lipids to the 
formation of various protein structures on the liposomal surface is negligible.  
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A) Structure of plain metallochelating liposome (TEM) B) Structure of metallochelating liposome with 
OspC bound onto the surface (white arrows – OspC); black arrow – OspC marked by 10nm 
immunogold particles; small red arrow – bead chain of OspC molecules; C) Schematic presentation of 
bead chain model of proteoliposome D) Size distribution and hydrodynamic diameter of OspC, plain 
metallochelating liposomes and OspC proteoliposomes analysed by DLS. The size distribution of parent 
monodispersed metallochelating liposomes (dashed line) was compared with that of OspC 
proteoliposomes (full line). As a reference, size distribution of OspC (dotted line) is shown. Numbers in 
brackets represent mean hydrodynamic diameters of particles 
Fig. 13. Characterisation of OspC preoteoliposomes. 
This is advantageous for study of protein-protein interaction of proteins anchored on the 
surface of liposomes. Moreover, anchoring of proteins via metallochelating bond produces 
highly oriented binding of proteins because the proteins are attached to liposomes 
exclusively by His-tagged end of the polypeptide chain. If some interaction between 
liposomal surface bound proteins exists, we can observe formation of various structures 
which are conditioned by the character and number of protein-protein interactions. Another 
important feature of metallochelating proteoliposomes is relatively high surface 
concentration of proteins. This concentration could be set by changing the DOGS-
NTA/phosphatidyl choline ratio in the lipid mixture used for preparation of liposomes. 
The ultrastructure of the rOspC-His-tag proteoliposomes was revealed by TEM (Fig. 7). 
rOspC-His tag as an example of the preoteoliposomal structure “Bead chain” model. 
Binding of individual molecules of OspC protein onto the liposomal surface is clearly visible 
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on the rim of the liposome and immunogold staining confirmed the identity of OspC 
molecules as well as preservation of the epitopes recognised by polyclonal antibodies (Fig. 
7b). In the case of recombinant OspC, TEM micrograph (Fig. 7b) showed that the individual 
molecules of OspC antigen were bound onto the surface of the liposome and some 
organisation in beads-like structures was revealed. This observation testifies against the 
simplification of the proteoliposomal structures and hence against accepting the simple 
schematic concept based on the random distribution on the liposomal surface.  
Binding of OspC onto the surface of metallochelating liposomes was proved by an increase 
of hydrodynamic diameter as assayed by DLS. The increase of the size of proteoliposomes is 
well distinguished from plain liposomes, even if the increase of the size is only 5.5 nm (Fig.. 
13D). This precise measurement was allowed by a preparation of parent monodispersed 
metallochelating liposomes and pointed to the importance of using monodispersive 
liposomal preparation for such a study (Fig. 8). In the case of homogenous coating of 
liposomes by OspC, the increase in the size should be of about 7.4 nm, theoretically. A lower 
increase of the size (5.5 nm) indicates only partial coating of the liposomal surface by the 
protein and this is in a good accordance with the structure revealed by TEM (Fig. 7b). 
Binding of OspC onto metallochelating liposomes was confirmed also by GPC used as an 
independent method (Fig. 9) The liposomal fraction was separated from free protein and 
OspC was assayed by SDS PAGE followed by immunoblot (Fig. 9C). The vast majority of 
OspC was shown to be bound onto liposomes and was only slightly ripped from their 
surface by shearing forces taking place during penetrating through GPC column. The tailing 
character of the OspC elution profile is supportive to this explanation. Stability of the 
metallochelating bond in model biological fluid was studied by incubation in undiluted 
human serum. In spite of the presence of serum, it was estimated that more than 60% of 
OspC was still associated with liposomes. Based on this data, the half life of OspC 
proteoliposomes in serum was estimated to be at least 1 hour. 
 
 
Fig. 14. Stability analysis of OspC proteoliposomes by GPC.   
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Non-bound OspC was separated from the proteoliposomes by gel permeation 
chromatography using Superose 6 column. OspC was detected in various fractions from 
GPC by immunoblot. OspC GPC elution profile is correlated with immunoblot assay.  
5.3 Immunization experiments 
New synthetic nonpyrogenic lipophilic analogues of NorAbu-MDP modified at a peptide 
part by two different hydrophobic ligands (Fig. 15) and for the first time these defined 
synthetic molecules were used in combination with metallochelating liposomes to 
construct an experimental recombinant vaccine. The important finding was that both 
MT06 and MT05 adjuvants exerted a high adjuvant effect comparable or better than MDP 
but proved itself as nonpyrogenic (rabbit pyrogenicity test) and safe. While alum induced 
stronger antibody response in IgG1 subtype, both MT06 derivatives and liposomal-MDP 
induced stronger immune response in both IgG2 subtypes. Interestingly, in comparison 
with MT06, the analogue MT05 induced stronger response in IgG1, IgG3 and IgM 
isotypes, respectively. This interesting finding pointed on the effect of lipophilic residues, 
which could not be supposed as the only accessory part of the molecule, but can 
significantly affect the quality of immune response. The position (peptide or sugar part) 
and the character (hydrophobicity and bulkiness) of the lipophilic function can affect the 
interaction with appropriate receptors as well as the metabolic degradation of the 
molecule. This aspect has not been described in the literature yet and is of interest for our 
understanding of the mechanism of action. 
OspC itself did not elicit detectable OspC-specific antibodies of IgG, IgM, and IgA isotypes 
(Ig*). Similarly, when OspC bound onto the surface of liposomes was used for 
immunisation, only negligible increase of OspC-specific Ig* was detected after the second 
immunisation. In contrast, immunisation with OspC plus adjuvants (FCA, AlOH, MDP, 
MT05, and MT06) elicited strong OspC-specific antibody responses with ELISA titres of the 
same magnitude. The contributions of particular IgG isotypes for the immune response 
showed differences among various adjuvants (Fig. 15) (FCA was no tested for the IgG 
isotype response).  
Mice (5 per group) were immunised by i.d. application of various liposome - adjuvant 
formulations of rOspC. Pooled sera from each group were used for ELISA analysis of 
specific antibodies titers. Naive sera were obtained before immunisation. ELISA plates were 
coated with 100 µl of rOspC (1 µg/ml), incubated with anti-mouse IgG1 (A), anti-mouse 
IgG2a (B), anti-mouse IgG2b (C), anti-mouse IgG3 (D), or anti-mouse IgM (E) and after 
addition of OPD plus H2O2, the absorbance was read at 490 nm on ELISA reader. The 
results are expressed as the end point titers +/- SD. Mean values are expressed in the table 
under each graph. Formulae of tested compounds in this experiment (F). 
Although AlOH adjuvant induced strong OspC-specific antibody responses in total 
immunoglobulin level (Ig*) and IgG1 isotype (Fig. 15A), the response in complement-
activating IgG isotypes (IgG2a and IgG2b; (Fig. 15B,C) was only modest. In comparison 
with AlOH, the synthetic adjuvant MT06 when combined with liposomes-bounded OspC 
induced strong OspC-specific response in isotypes IgG2a and at lesser extent in IgG2b 
(Fig. 15B). Application of another synthetic adjuvant MT05 was associated with 
dominancy of IgG3 and IgM (Fig. 15D,E). Furthermore, we compare responses to 
synthetic norAbu-MDP adjuvants with the response to liposomes-bounded OspC plus 
MDP, which elicits strongest OspC-specific antibodies in IgG2b and in lesser extent in 
IgG2a isotype (Fig. 15B,C). 
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Fig. 15. ELISA analyses of specific antibody titers in sera of immunised mice.  
6. Conclusion 
Liposomes offer an interesting alternative to aluminium hydroxide and other adjuvant 
systems, especially in those cases, when the induction of cell immunity is of importance. 
Various methods for preparation of proteoliposomal vaccination particles are developed 
and metallochelating liposomes represent the newest and versatile approach to this 
problem. New nonpyrogenic lipophilic derivatives of norAbu-MDP have been shown to be 
potent adjuvants for week antigens like recombinant nonlipidized OspC and are suitable 
adjuvant components, together with other synthetic adjuvants like MPLA and CpG oligos, 
for construction of vaccines based on various liposomal platforms. Adjuvant potency of 
these new MDP analogues is comparable to MDP but they lack side effects related to MDP, 
like strong pyrogenicity and flu like syndromes. Also other synthetic adjuvans like (MPL-A 
and CpG oligonucleotides) or could be entrapped in metallochelating liposomes alone or in 
their combinations to precisely tailor the immune response towards particular antigen, 
especially if the Th1 response is of interest.  
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Moreover, liposomes are also applicable for non-invasive routes of application as mucosal 
and transdermal ones, and if rationally designed and applied with new synthetic adjuvants 
derived from PAMP, they are able to steer the immune system towards desired effective 
response. The most important observation was that in all vaccinated animals liposomal 
based vaccines did not induce any side effects. Application of modern physico-chemical and 
microscopic methods for study of the structure and stability of proteoliposomal vaccination 
particles is indispensable part of successful development of modern safe and effective 
vaccines.  
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